Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours
- 17 September 2011
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 39 (1) , 72-82
Abstract
Although somatostatin receptor positron emission tomography (PET)/CT is gaining increasing popularity and has shown its diagnostic superiority in several studies, 111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide is still the current standard for diagnosis of neuroendocrine tumours (NET). The aim of this study was to compare the costs for the two diagnostic tests and the respective consequential costs.Keywords
This publication has 29 references indexed in Scilit:
- Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumoursActa Oncologica, 2010
- Consensus Recommendations for the Diagnosis and Management of Well-Differentiated Gastroenterohepatic Neuroendocrine Tumours: A Revised Statement from a Canadian National Expert GroupCurrent Oncology, 2010
- 111In-pentetreotide scintigraphy: procedure guidelines for tumour imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine TumorsNeuroendocrinology, 2009
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and DocumentationNeuroendocrinology, 2009
- Molekulare Bildgebung neuroendokriner Tumoren mit68Ga-markierten Peptiden (Somatostatinrezeptor-PET/CT)Der Nuklearmediziner, 2009
- Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinationsNuklearmedizin-Nuclear Medicine, 2009
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological ExaminationsNeuroendocrinology, 2008
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997